June 16-19, 2025

Boston Convention & Exhibition Center

2024 Sessions

Review the sessions from BIO 2024 and see the caliber of content you can expect at BIO 2025.

 
Loading
Search Filters
  • Date
  • Session Type
  • Focus Area
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
6:30 AM – 9:00 AM
(PST)
  1. KBI Biopharma 5K at BIO 2024
    Session
9:00 AM – 12:00 PM
(PST)
  1. Partnering with the U.S. Government to Achieve Our National Security Mission
    Breakout Session
    • Infectious Disease and Vaccines
    28ABCDE
10:00 AM – 11:00 AM
(PST)
  1. APAC: A Top Rate Destination for Complex and Challenging Clinical Trials
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Sponsored by:
    novotech
    Judith Ng-Cashin
    Judith Ng-Cashin, Chief Medical Officer - Novotech
    Zach Gobst
    Zach Gobst, Founder and CEO - Leapcure
    Srini Ramanathan
    Srini Ramanathan, Chief Development Officer - Roivant
    Yao Li Ho
    Yao Li Ho, Managing Director - LYFE Capital
    Mark Tang
    Mark Tang, Managing Director - Good Health Capital
    Han Ying
    Han Ying, Chief Executive Officer - Gyre Therapeutics
11:00 AM – 11:45 AM
(PST)
  1. Funding from a Japanese Investment Perspective
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Amy Nguyen
    Amy Nguyen, Vice President, Business Development and Relationship Management - Catalyst Clinical Research
    Takaaki Tobaru
    Takaaki Tobaru, Partner - Remiges Ventures
    Scott Kahn
    Scott Kahn, Chairman, ICAN Biomarkers Council; Founder - Alykomed Global Solutions LLC
    Ryusuke Sakamoto
    Ryusuke Sakamoto, General Manager, Business Development - Sanwa Kagaku Kenkyusho Co., Ltd.
11:30 AM – 1:00 PM
(PST)
  1. Premier & General Attendee Lunch
    Session Sails Pavilion
12:00 PM – 1:00 PM
(PST)
  1. How to Build a Successful and Competitive Biopharma Ecosystem in Southeast Asia
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Mai Zymaris
    Mai Zymaris, Counsel - Baker McKenzie
    Phong Tran
    Mr. Phong Tran, CEO - BOUND Therapeutics and siRnaMed Therapeutics
    Anh Hoang-Lindsay
    Anh Hoang-Lindsay, CEO - Jana Care
    John Mattison
    John Mattison, Operating Partner and Chief Medical Information Officer - Arsenal Capital Partners
    Alex Wang
    Alex Wang, Head of Business Development, US & China - Zuellig Pharma
12:15 PM – 6:00 PM
(PST)
  1. Company Presentations Monday
    Company Presentation Session Company Presentation Theaters
    Sponsored by:
    johnson and johnson
12:30 PM – 1:30 PM
(PST)
  1. Sustainable Talent Development for Biomanufacturing of the Future
    BioProcess Theater BioProcess Theater
    Sue Behrens
    Sue Behrens
    Mike Alston
    Mike Alston, Vice President, Operations - Avid Bioservices
    John Belchunas
    John Belchunas
    Gargi Ghosh
    Gargi Ghosh, Associate Professor - Keck Graduate Institute
    Keau Wong
    Keau Wong
1:00 PM – 1:45 PM
(PST)
  1. APAC Summit Networking Lunch
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
1:45 PM – 2:45 PM
(PST)
  1. A Discussion on Increasing Healthspan
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Hilary Brueck
    Hilary Brueck, Journalist - Business Insider
    Dan Oliver
    Mr. Dan Oliver, CEO & Co-Founder - Rejuvenate Bio
    Alex Aravanis
    Dr. Alex Aravanis, CEO - Moonwalk Biosciences
    Jake Becraft
    Jake Becraft, CEO & Founder - Strand Therapeutics
    Katharine Grabek
    Katharine Grabek, Co-Founder and CSO - Fauna Bio
    Jennifer Bergheiser
    Jennifer Bergheiser, Chief Business Officer - eGenesis
  2. A Licensing Deal for All Seasons
    Breakout Session
    • Business Development and Finance
    29AB
    Jonathan Grinstein
    Jonathan Grinstein, Senior Editor - Inside Precision Medicine
    Uneek Mehra
    Uneek Mehra, CHIEF FINANCIAL & BUSINESS OFFICER - 4DMT
    Kunal Patel
    Mr. Kunal Patel, VP of Business Development - Synthekine
    Gavin Samuels
    Dr. Gavin Samuels, Chief Business Officer - CinRx Pharma
    Lesley Stolz
    Lesley Stolz, Vice President - Johnson & Johnson Innovation
    Richard Wilson
    Richard Wilson, Senior VP, Primary Focus Lead of Genetic Regulation - Astellas Gene Therapies
  3. All Money is NOT Created Equal: The Differences between Angel, Venture and Strategic Capital in the Biotech Funding Ecosystem
    Breakout Session
    • Business Development and Finance
    32AB
    Yaniv Sneor
    Mr. Yaniv Sneor, Founder & Managing Director - Mid Atlantic Bio Angels
    Jonathan McClain
    Jonathan McClain, Executive Director, Eli Lilly Catalyze team - Eli Lilly
    Max Farina
    Dr. Max Farina, Senior Associate - 5AM Ventures
    Alexey Konov
    Alexey Konov, Managing Partner - Biovision Ventures
  4. Alternative Funding Programs: Protecting Patients in an Ever-Changing Healthcare Landscape
    Breakout Session
    • Patient Advocacy
    26A
    Ashira Vantrees
    Ashira Vantrees, Counsel - Aimed Alliance
    Kim Czubaruk
    Kim Czubaruk, Associate Vice President of Policy - Cancer Care
    Kollet Koulianos
    Kollet Koulianos, Senior Payer Advisor - Hemophilia Alliance
    Richard Meyers
    Richard Meyers, Head, State Policy - Bristol Myers Squibb
    Theresa Alban
    Theresa Alban, Senior Manager, Federal Policy - Cystic Fibrosis Foundation
  5. Building Capacities in the Industry for Secondary Uses of Health Data: The EHDS Framework
    Breakout Session
    • AI and Digital Health
    24BC
    Montse Daban
    Dr. Montse Daban, Director of Strategic Foresight at Biocat; President - CEBR
    Jean Marc Bourez
    Dr. Jean Marc Bourez, CEO - EIT Heatlth
    Elina Drakvik
    Ms. Elina Drakvik, Senior lead, Health Data 2030 - Sitra
    Aenor Sawyer
    Aenor Sawyer, Director UC Space Health - University of San Francisco
    Brad Ship
    Brad Ship, Partner - Alira Health
    Chris Morton
    Chris Morton, Business Executive and CEO - ELEM Biotech
  6. Empowering Real World Patient-Centric Digital Health in Asia with Digital Apps
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Peter Kurz
    Peter Kurz, Chief Strategy Officer - QIC International
    Yen-Yin Lin
    Yen-Yin Lin, Co-founder & CEO - JelloX Biotech Inc.
    Edward Deng
    Edward Deng, co-founder and CEO - Health2Sync
    Amy Hsiao
    Amy Hsiao, Head of Product Management - Acer Medical
    Jarret Chia-Ju Su
    Jarret Chia-Ju Su, Co-Head of Healthcare & Life Science - KPMG in Taiwan
    Steven Lester
    Steven Lester, Cardiologist and Professor in Medicine - Mayo Clinic
  7. Europe's Policy Environment and the Impact on the Biotech Sector
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Justin Pine
    Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)
    Steffen Thirstrup
    Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Claire Skentelbery
    Dr. Claire Skentelbery, Director General - EuropaBio
    Matias Olsen
    Matias Olsen, Public Affairs & Policy Manager - EUCOPE
    Santoke Naal
    Santoke Naal, Managing Director - IGES UK
    Thomas Bols
    Thomas Bols, Head of Government Affairs and Patient Engagement, EMEA & APAC - PTC Therapeutics
  8. Super Session
    Fireside Chat with Nauman Shah, Global Head of Business Development, Johnson & Johnson Innovative Medicine
    Super Session
    • Business Development and Finance
    28ABCDE
    Sponsored by:
    johnson and johnson
    Michelle Davis
    Michelle Davis, M&A Reporter - Bloomberg News
    Nauman Shah
    Nauman Shah, Global Head of Business Development - Johnson & Johnson Innovative Medicine
  9. Lessons from the Oregon Trail: Pioneering Gene Therapy in the Real World
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Tom Klima
    Tom Klima, Chief Operating and Commercial Officer - bluebird bio
    Joe Garrity
    Mr. Joe Garrity, Senior Director, Head of Cell and Gene Therapy Customer Proposals - Lonza
    Tim Olson
    Tim Olson, Medical Director, Blood and Marrow Transplant Program - Children's Hospital of Philadelphia
    Michelle Campbell
    Michelle Campbell, Caregiver - N/A
    Kirk Davis
    Kirk Davis, Cigna Healthcare Gene Therapy Program, Senior Manager - Cigna
  10. The Cross-Border Applicability of RWD in Decision-Making
    Breakout Session
    • Regulatory Innovation
    31C
    Rachel Ehlers
    Rachel Ehlers, Partner - Baker McKenzie
    Michele Colucci
    Michele Colucci, Founder & Managing Partner - DigitalDx Ventures
    Michelle Wong
    Michelle Wong, Head of Operations - Octant
    Jonathan Fairtlough
    Jonathan Fairtlough, Principal, Advisory, Cyber Security Services - KPMG US
    Virginia Sanzone
    Virginia Sanzone, General Counsel - ICU Medical
  11. The Time is Now: Global Perspectives on Preparing for Public Health Emergencies
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Sponsored by:
    Emergent logo
    Chris Frech
    Chris Frech, Senior Vice President Global Government Affairs - Emergent BioSolutions
    Wolfgang Philipp
    Wolfgang Philipp, Principal Advisor – Chief Science Officer - HERA
    Brett Sutton
    Brett Sutton, Director, Health & Biosecurity - CSIRO
    Oliver Schacht
    Oliver Schacht, Executive VP Corporate Development - OpGen
    Ambika Bumb
    Ambika Bumb, Deputy Executive Director - Bipartisan Commission on Biodefense
2:00 PM – 2:45 PM
(PST)
  1. Digital Transformation for Start-up and Mid-sized Life Science manufacturing sites
    BioProcess Theater BioProcess Theater
    John Clapham
    John Clapham
3:00 PM – 4:00 PM
(PST)
  1. A New Era for Access and Affordability: Considerations for Patients and Manufacturers in a Post-IRA World
    Breakout Session
    • Patient Advocacy
    26A
    Mark Gooding
    Mark Gooding, Managing Director - Avalere
    Anna Hyde
    Anna Hyde, Vice President of Advocacy and Access - Arthritis Foundation
    Valerie Reynolds
    Valerie Reynolds, Executive Director - Genentech
    Eric Gascho
    Eric Gascho, Senior Vice President, Policy and Government Affairs - National Health Council
  2. A Perspective from the Trenches: Challenges of Budgeting for Gene Therapies, Innovative Payment Systems That Work for Medicaid Departments and Patients, and What the States Need from CMS
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Thomas Barker
    Thomas Barker, Partner - Foley Hoag LLP
    Scott McGoohan
    Scott McGoohan, Executive Director, Policy and Alliance Development - Vertex Pharmaceuticals
    Jay Newman
    Mr. Jay Newman, SVP, Commercial Development, Pricing & Reimbursement - Spark Therapeutics, Inc.
    Stuart Portman
    Stuart Portman, Executive Director, Division of Medical Assistance Plans - State of Georgia
    James Uli
    James Uli, Senior Vice President and Chief Financial Officer - Rady Children's Hospital and Health Center
  3. AI and Regulatory Innovation in Healthcare: Shaping the Future
    Breakout Session
    • Regulatory Innovation
    31C
    Paul Howard
    Paul Howard, Senior Director, Public Policy - Amicus Therapeutics
    Meredith Brown-Tuttle
    Meredith Brown-Tuttle, Chief Regulatory Strategist - Regulatorium
    Brandon Rice
    Brandon Rice, Chief Product Officer - Weave Bio
    Christopher Hart
    Christopher Hart, Partner - Foley Hoag
    Mida Pezeshkian
    Mida Pezeshkian, Founder, Principle - STEMA_cg
  4. An Insider Look at Top Deals from 2023
    Breakout Session
    • Business Development and Finance
    29AB
    Carin Canale-Theakston
    Carin Canale-Theakston, Executive Biotech Advisor - Inizio
    Ken Song
    Ken Song, former CEO - RayzeBio
    Enoch Kariuki
    Enoch Kariuki, President - Endeavor Biomedicines
    Mark McKenna
    Mark McKenna, CEO - Mirador Therapeutics
    Remy Durand
    Remy Durand - Vertex
  5. Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment
    Breakout Session
    • Business Development and Finance
    32AB
    Arda Ural
    Mr. Arda Ural, Americas Life Sciences Sector Leader - EY (Ernst & Young)
    Chris Garabedian
    Mr. Chris Garabedian, VC Portfolio Manager - Perceptive Advisors
    Barbara Ryan
    Ms. Barbara Ryan, Board Member, Senior Advisor to EY, Indivior, Mink, Invo, SafeCor Pharmaceutical Companies
    Brian Bronk
    Brian Bronk, Head of Business Development, Neurology, Rare Diseases, Technology Platforms and R&D Transactions Partnering - Sanofi
    Julie Rozenblyum
    Julie Rozenblyum, Senior Vice President, Business Development - BMS
  6. Capabilities for Advanced Biomanufacturing: Enhancing opportunities and meeting challenges for global access
    BioProcess Theater BioProcess Theater
    Rob Welsh
    Rob Welsh, VP-Biopharma Production Solutions - Avantor
    Ilya Goldberg
    Ilya Goldberg, Chief Science Officer - ViQi
    Flaka Radoniqi
    Flaka Radoniqi, Principal Scientist, Pivotal Biologics Drug Substance Technologies - Amgen
    Craig Vincze
    Craig Vincze, Vice President and Co-founder - Alphinity
  7. Emerging Technologies Fostering Biotech Innovation Globally
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Falk Ehmann
    Dr. Falk Ehmann, Head of Innovation and Development Accelerator (IDeA) - European Medicines Agency (EMA)
    Blythe Adamson
    Dr. Blythe Adamson, Senior Principal Scientist, Head of Outcomes Research - Flatiron Health
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
    Robert Schröder
    Robert Schröder, Head of Sector External Communication (EISMEA) - European Innovation Council
    Mahesh Yadav
    Mahesh Yadav, Distinguished Scientist - Genentech
    Ferenc Marofka
    Ferenc Marofka - European Commission
  8. Fireside Chat
    Fireside Chat with Nina Kjellson, General Partner, Canaan Partners
    Fireside Chat
    • Business Development and Finance
    30DE
    Allison DeAngelis
    Ms. Allison DeAngelis, Reporter - STAT News
    Nina Kjellson
    Nina Kjellson, General Partner - Canaan Partners
  9. Fireside Chat
    Fireside Chat with Stephen Quake, Head of Science, Chan Zuckerberg Initiative
    Fireside Chat
    • Next Generation Biotherapeutics
    25ABC
    Jonathan Wosen
    Jonathan Wosen, West Coast Biotech & Life Sciences Reporter - STAT
    Steve Quake
    Steve Quake, Head of Science - Chan Zuckerberg Initiative
  10. Forging New Pathways to Reimbursement for Digital Therapeutics: Considerations for Payer Coverage
    Breakout Session
    • AI and Digital Health
    24BC
    Brigit Kyei-Baffour
    Brigit Kyei-Baffour, Principal - Avalere
    Jon Campbell
    Jon Campbell, Chief Science Officer - National Pharmaceutical Council
    Dirk Soenksen
    Dirk Soenksen, Co-founder and CEO - Ceresti Health
    Chris Koch
    Chris Koch, CEO - LeGen Medicial Devices
    Beth Rogozinski
    Beth Rogozinski, CEO - Oncoustics
  11. Global Policy Perspectives on the Next Generation of Rare Disease Medicines
    Breakout Session
    • Orphan and Rare Disease
    28ABCDE
    Sponsored by:

    merck logo

    Jannie Oosthuizen
    Jannie Oosthuizen, President, Merck Human Health U.S. - Merck
    Karin Hoelzer
    Dr. Karin Hoelzer, Senior Director, Policy and Regulatory Affairs - National Organization for Rare Disorders (NORD)
    Ryan MacFarlane
    Ryan MacFarlane, Vice President - Access Partnership
    Durhane Wong-Rieger
    Durhane Wong-Rieger, President & CEO - Canadian Organization for Rare Disorders (CORD)
    His Excellency Mansoor Al Mansoori
    His Excellency Mansoor Al Mansoori, Abu Dhabi Executive Council Member and Chairman of the Department of Health - Abu Dhabi
  12. Let’s Go STEDI: Moving Beyond QALY’s to Understand the True Value of Antimicrobials and Vaccines
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Ted Buckley
    Dr. Ted Buckley, Vice President, Government Affairs - Shionogi
    Ella Balasa
    Ms. Ella Balasa, Patient Expert - Balasa Consulting
    Scott Johnson
    Dr. Scott Johnson, CEO/Founder - Medicus Economics
    John Rex
    Dr. John Rex, Chief Medical Officer - F2G
  13. Longevity Therapeutics Enter Biopharma Mainstream
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Brian Gormley
    Brian Gormley, Reporter - Wall Street Journal
    Simone Fantaccini
    Dr. Simone Fantaccini, Chief Scientific Officer & Head of Medical Affairs - Novartis
    Cristina Ghenoiu
    Cristina Ghenoiu, Investor - Mubadala Capital
    Robert Gould
    Robert Gould, Operating Partner - Khosla Ventures
    Marco Quarta
    Dr. Marco Quarta, Founder and CEO - Rubedo Life Sciences
    Hanadie Yousef
    Hanadie Yousef, Chief Executive Officer and Co-Founder - Juvena Therapeutics
  14. Patients Wait Less: Streamlining Regulatory Pathways for Cell/Gene Therapies in Asia-Pacific Region
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Wallace Lin
    Dr. Wallace Lin, Secretary-General - Taiwan BIO
    Joseph Damond
    Joseph Damond, Chair, Global Life Sciences - Crowell & Moring International LLC
    Chia-Hua (Maggie) Ho
    Dr. Chia-Hua (Maggie) Ho, Chief Operating Officer - Amarex Taiwan, LLC
    Yueh-Ping Liu
    Dr. Yueh-Ping Liu, Director-General, Department of Medical Affairs - Ministry of Health and Welfare of Taiwan
    Yoshiaki Maruyama
    Yoshiaki Maruyama, Review Director at the Office of Cellular and Tissue-based Products - PMDA
4:00 PM – 4:15 PM
(PST)
  1. Investissement Québec International
    Global Innovation Hub 30 December 1899 05:00:00
    Georges Ged
    Mr. Georges Ged, Senior Director Foreign Direct Investment - Life Sciences & Health Technologies - Investissement Québec International
4:15 PM – 5:15 PM
(PST)
  1. Agile Biologics Development and Manufacturing Strategies to Meet Market Demand
    Breakout Session
    • Business Development and Finance
    30DE
    Sponsored by:
    thermofisher scientific
    Paul Jorjorian
    Paul Jorjorian, Vice President & General Manager, Biologics, Pharma Services - Thermo Fisher Scientific
    Glen Campbell
    Glen Campbell, Vice President, Head of External Operations - Vir Biotechnology
    Michael Deperro
    Michael Deperro, SVP, Corporate Development - Rezolute Inc
    Adam Pfeiffer
    Adam Pfeiffer, Vice President - Farma Project
  2. Altering the Regulatory Ecosystem for Pediatric Clinical Programs: Intended and Unintended Consequences
    Breakout Session
    • Regulatory Innovation
    31C
    Catherine Lee
    Dr. Catherine Lee, Associate Director, Global Regulatory Policy and Intelligence - Johnson & Johnson
    Laurie Conklin
    Dr. Laurie Conklin, Senior Director, Pediatric Development - Johnson & Johnson
    Dionna Green
    Dr. Dionna Green, Director, Office of Pediatric Therapeutics - FDA
    Thomas Miller
    Dr. Thomas Miller, Global Head, Acute, Chronic & Pediatric Disease Nucleus - Bayer
  3. Avoid the Cycle of “Panic and Neglect": How Ongoing Commitment to Innovative Partnerships Futureproofs Against the Next Pandemic
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Paul Friedrichs
    Paul Friedrichs, Maj. Gen. (ret), Deputy Assistant to the President - Director of the Office of Pandemic Preparedness and Response at the White House
    Georges Benjamin
    Dr. Georges Benjamin, Executive Director - American Public Health Association
    Dawn O'Connell
    Ms. Dawn O'Connell, Assistant Secretary for Preparedness and Response (ASPR), HHS - U.S. Department of Health and Human Services
    Emma Wheatley
    Ms. Emma Wheatley, Director, Access and Private Partnerships - CEPI
    Laurent Muschel
    Laurent Muschel, Acting Director General - European Commission, Health Emergency Preparedness and Response Authority (HERA)
    Kelly Cappio
    Kelly Cappio, Vice President, Global Policy and Government Affairs - Novavax
  4. Creative Structures for Keeping Innovation Alive After the Deal
    Breakout Session
    • Business Development and Finance
    29AB
    Oren Livne
    Mr. Oren Livne, Partner - Baker McKenzie
    Gavin Liu
    Gavin Liu, Senior Director, Legal Strategic Transactions - Astellas
    Deepa Talpade
    Deepa Talpade, Vice President, Head BD&L and Alliance Mgmt., Oncology - Bayer
    Maria Nichol
    Maria Nichol, Chief Business Officer - Artax Biopharma
    Ellen Lubman
    Ellen Lubman, Chief Business Officer - Werewolf Therapeutics
    Casarine Chong
    Casarine Chong, Senior Vice President, Deputy General Counsel, Transactions - Bristol Myers Squibb
  5. Fireside Chat
    Fireside Chat with Matt Gline, CEO, Roivant Sciences
    Fireside Chat
    • Business Development and Finance
    25ABC
    Michelle Davis
    Michelle Davis, M&A Reporter - Bloomberg News
    Matt Gline
    Matt Gline, Chief Executive Officer - Roivant Sciences
  6. From Patients to Partners: Patient Advocacy and Biotech Collaborate to Accelerate Innovation
    Breakout Session
    • Patient Advocacy
    26A
    Anthony Mancini
    Anthony Mancini, EVP & Chief Operating Officer - Genmab
    Meghan Gutierrez
    Meghan Gutierrez, CEO - Lymphoma Research Foundation
    Portia Badham
    Portia Badham, Patient Advocate and Marketing/Communications Consultant
    Sabine Haubenreisser
    Dr. Sabine Haubenreisser, Principal Scientific Administrator, Stakeholders and Communications Division - European Medicines Agency (EMA)
  7. Gun Violence Prevention: A Case Study in Passing Meaningful Policies in a Hyper Partisan Era
    Special Program
    • Regulatory Innovation
    28ABCDE
    Josh Horwitz
    Josh Horwitz, Co-director - Johns Hopkins Center for Gun Violence Solutions
    Angus McQuilken
    Angus McQuilken, co-founder - Life Sciences to End Gun Violence Epidemic
    Traci Murphy
    Traci Murphy, Executive Director - Delaware Coalition Against Gun Violence and Coalition For A Safer Delaware
    Jen Pauliukonis
    Jen Pauliukonis, Director of Policy and Programming - Johns Hopkins Center for Gun Violence Solutions
  8. Innovation Passport: Emerging Opportunities for Company Growth in Global Markets
    Breakout Session
    • Business Development and Finance
    32AB
    Susie Harborth
    Ms. Susie Harborth, Chief Business Officer - Breakthrough Properties
    Bernard Parker
    Bernard Parker, Chief Business Officer - Shanghai Pharma Biotherapeutics USA, Inc.
    Kristen Albright
    Dr. Kristen Albright, CEO - Prokarium
    Avi Spier
    Dr. Avi Spier, Executive Director Business Development and Licensing - Novartis
    Wen Qi Ho
    Wen Qi Ho, Therapeutics Lead - ClavystBio
  9. Investors' Perspectives: Digital Health Trends and Investment Thesis in 2024 and Beyond
    Breakout Session
    • AI and Digital Health
    24BC
    Josh Seidenfeld
    Josh Seidenfeld, Partner and Chair, Digital Health - Cooley LLP
    Mara Aspinall
    Mara Aspinall, Partner - Illumina Ventures
    Sourav Kole
    Sourav Kole, Managing Director - Dolby Family Ventures
    Matt Blum
    Matt Blum, Principal - Cigna Ventures
    Christina DelloRusso
    Christina DelloRusso, Partner - LRVHealth
  10. Quality Standards for Final Preparation of CGT Product at Point of Care (POC)
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Maria Amaya
    Dr. Maria Amaya, Lead External Advocacy, Quality Policy and Advocacy - Genentech, A member of the Roche Group
    Maria Sørensen
    Dr. Maria Sørensen, Specialist, RA CMC Lead - Novo Nordisk
    Lesbeth Rodriguez
    Dr. Lesbeth Rodriguez, Director, Regulatory Affairs, Policy and Innovation - Bayer
    Steffen Thirstrup
    Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Heather Lombardi
    Heather Lombardi, Director, Office of Cellular Therapy and Human Tissue - FDA
  11. Unlocking Biotech Growth: Hong Kong as the Gateway to Global Markets
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Sponsored by:
    hkstp
    Albert Wong
    Albert Wong, CEO - Hong Kong Science and Technology Parks Corporation
    Michael Chen
    Michael Chen, CEO & Co-founder - Great Bay Bio Limited
    Grace Lau
    Grace Lau, Head, Institute for Translational Research - Hong Kong Science and Technology Parks Corporation
    Andy Wong
    Andy Wong, Head of Innovation and Technology - Invest Hong Kong
    Gaobo Zhou
    Gaobo Zhou, Chief Investment Officer - Simcere Pharmaceutical Group Limited
    Vicky Qu
    Vicky Qu, Senior Vice President and Chief of Staff - BioMap
  12. Unlocking Success to Biotech Global Expansion: A Stepwise Game Plan for International Launch
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Eduardo Schur
    Eduardo Schur, US Health Sciences & Wellness Commercial Strategy and R&D Lead - EY (Ernst & Young)
    Ger Brophy
    Ger Brophy, Chair of the Scientific Advisory Board and retiring EVP Biopharma Production - Avantor
    Russell Cox
    Russell Cox, President & CEO - Epirium Bio
    Robert LaCaze
    Robert LaCaze, CEO - Mnemo Therapeutics
    Tolga Tanguler
    Tolga Tanguler, CCO - Alnylam Pharmaceuticals
    Jérôme Revole
    Jérôme Revole, Managing Director Healthcare and Lifesciences - Business France North America
  13. Use of AI in mRNA: The New Revolution?
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Andy French
    Andy French, Director, Data & AI - CGI
    Mathieu Blanchette
    Dr. Mathieu Blanchette, Director - McGill University
    Christian Barrow
    Christian Barrow, Executive Director - J.P. Morgan
    Petrina Kamya
    Dr. Petrina Kamya, Vice President and Global Head of AI Platforms, Insilico Medicine - President, Insilico Medicine Canada
    Andrew Giessel
    Andrew Giessel, Executive Director - Moderna
    Ashoka Madduri
    Ashoka Madduri, Head of Scientific Strategy and CI - mRNA CoE, Sanofi
4:30 PM – 5:00 PM
(PST)
  1. Japan - Global Innovation Hub
    Global Innovation Hub 30 December 1899 05:00:00
    Nobutaka Maekawa
    Nobutaka Maekawa, Executive Vice President - Japan External Trade Organization (JETRO)
    Hirokazu Shimoda
    Hirokazu Shimoda, Director, Bio-Industry Division, Commerce and Service Industry Policy Group - Ministry of Economy, Trade and Industry (METI)
    Mikiro Suga
    Mikiro Suga, Senior Coordinator, Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management, Health Policy Bureau - Ministry of Health, Labour and Welfare of Japan (MHLW)
9:00 AM – 10:30 AM
(PST)
  1. Main Stage Opening Program
    Main Stage Program Ballroom 20
    Ted Love
    Dr. Ted Love, Chair - BIO Board of Directors
    Aaron Lazar
    Aaron Lazar, Actor, Singer, and Advocate
  2. The Convergence of Entrepreneurship and Innovation featuring Viola Davis
    Main Stage Program Ballroom 20
    Brooke Baldwin
    Brooke Baldwin, TV host, award-winning journalist and bestselling author
    Viola Davis
    Viola Davis, Award-Winning Actress, Producer, and New York Times Best-Selling Author
10:30 AM – 5:00 PM
(PST)
  1. Company Presentations Tuesday
    Company Presentation Session Company Presentation Theaters
    Sponsored by:
    johnson and johnson
  2. Overcoming Development, Scale Up and Commercial Production Challenges for Novel Modalities
    BioProcess Theater BioProcess Theater
11:00 AM – 12:00 PM
(PST)
  1. AI's Trial by Fire: Experimental Validation in Drug Discovery
    Breakout Session
    • AI and Digital Health
    24BC
    Nitya Sridhar
    Nitya Sridhar - Power
    Martin Akerman
    Dr. Martin Akerman, Co-founder and CTO - Envisagenics
    Michael Bemben
    Michael Bemben, Director, Data Science and External Innovation - Johnson & Johnson
    Stacie Calad Thomson
    Stacie Calad Thomson, Vice Chairperson - Alliance for AI in Healthcare (AAIH)
    Etai Jacob
    Etai Jacob, Senior Director, Head of Data Science and AI, Early Oncology - AstraZeneca
    Alex Zhavoronkov
    Alex Zhavoronkov, Founder and CEO - InSilico Medicine
  2. Brick-by-Brick: Building a Biotech from Foundation Up with Venture Investor Company Formation
    Breakout Session
    • Business Development and Finance
    26B
    Allison DeAngelis
    Ms. Allison DeAngelis, Reporter - STAT News
    Ann Lee-Karlon
    Ann Lee-Karlon, Chief Executive Officer and President - EpiBiologics
    Amy Liu
    Mrs. Amy Liu, Investor - Mubadala Capital
    Mitchell Mutz
    Mitchell Mutz, Entrepreneur Partner - Vivo Capital
    Sanjay Mistry
    Sanjay Mistry, Vice President - Johnson & Johnson Innovation
  3. Build Your Product Pipeline with Non-Dilutive Federal Resources
    Breakout Session
    • Business Development and Finance
    29AB
    Stephanie Fertig
    Ms. Stephanie Fertig, Director, NIH Small Business Program - National Institutes of Health (NIH)
    Elaine Haynes
    Ms. Elaine Haynes, President and CEO - KaloCyte, Inc.
    Julius Korley
    Julius Korley, Associate Vice President, Office of Economic Innovation and Partnerships - University of Delaware
    Meghan Wood
    Ms. Meghan Wood, Managing Director - New York Blood Center Ventures
    Anna Zornosa-Heymann
    Anna Zornosa-Heymann, Advisor, entrepreneur, investor Entrepreneur in Residence, National Institutes of Health (NIH) Advisor, Ignite Health Accelerator - Astia Fund and Hera Biotech
  4. Building a Bioscience Economy Through Supportive State Legislation: A Discussion with State Legislators from California, Massachusetts, and the Midwest
    Special Program
    • Regulatory Innovation
    29C
    Pete Pellerito
    Pete Pellerito, Senior Policy Adviser Federal/State Economic Development & Technology Transfer Lead - BIO
    John Lawn
    John Lawn, Massachusetts Representative - 10th District - Middlesex
    Cottie Petrie-Norris
    Cottie Petrie-Norris, California Assemblywoman - 73rd Assembly District – Costa Mesa, Irvine and Tustin
    Jordan Rasmusson
    Jordan Rasmusson, Minnesota Senator
    Chris Ward
    Chris Ward, California Assemblymember - 8th Assembly District - San Diego and El Cajon
  5. Super Session
    Decoding Biopharma's Public Image: Navigating 2024 Election Dynamics
    Super Session
    • Next Generation Biotherapeutics
    28ABCDE
    Sponsored by:
    Genentech logo
    Fritz Bittenbender
    Fritz Bittenbender, Senior Vice President - Genentech
    Neil Newhouse
    Neil Newhouse, Partner and Co-Founder - Public Opinion Strategies
    Kathleen Rice
    Hon. Kathleen Rice
    Greg Walden
    Hon. Greg Walden, Former Chair - US House Energy and Commerce Committee
  6. FDA Townhall
    Special Program
    • Regulatory Innovation
    25ABC
    Steve Berman
    Steve Berman, Deputy Vice President, Science and Regulatory Affairs Strategy - Biotechnology Innovation Organization (BIO)
    Peter Marks
    Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) - U.S. Food and Drug Administration
    Patrizia Cavazzoni
    Dr. Patrizia Cavazzoni, Director, Center for Drug Evaluation and Research - FDA
  7. In and Out of This World: Partnering with Federal Labs
    Breakout Session
    • Business Development and Finance
    32AB
    Vladimir Popov
    Vladimir Popov, Chief Innovation Officer - Frederick National Laboratory for Cancer Research
    Edward Diehl
    Edward Diehl, Commercialization Officer - U.S. Army Medical Research and Development Command
    Tara Kirby
    Tara Kirby, Director of the Office of Technology Transfer - National Institutes of Health
    Michael Roberts
    Dr. Michael Roberts, Chief Scientific Officer - International Space Station National Laboratory
    Gillian Fenton
    Gillian Fenton, Vaccines Legal Operations - GSK
    Lisa Thomas Read
    Dr. Lisa Thomas Read, Vice President, Research and Development - Amivas (US), LLC
  8. Italian Trade Agency
    Global Innovation Hub 30 December 1899 05:00:00
    Marco Cito
    Mr. Marco Cito, Head of the Foreign Investments Attraction Department - Italian Trade Agency
  9. Navigating the Future of Cell and Gene Therapy: Strategies for Innovation, Collaboration, and Market Success
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    30ABC
    Sponsored by:
    cencora
    Lung-I Cheng
    Lung-I Cheng, Vice President, Cell and Gene Therapy - Cencora
    Irene Agodoa
    Irene Agodoa, Senior Vice President, Head of Medical Affairs - Orca Bio
    Adriana Herrera
    Adriana Herrera, Chief Executive Officer - Pierre Fabre Pharmaceuticals
    Brad Martin
    Brad Martin, Vice President, Head of Market Access and Trade - Neurotech Pharmaceuticals
    Robert Sexton
    Robert Sexton, former Senior Vice President, Strategy & Program Execution - Mustang Bio
  10. New Pain Therapeutics: Strategies for Innovation, Investment, and Collaboration
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Hernan Bazan
    Dr. Hernan Bazan, CEO & Co-Founder - South Rampart Pharma, Inc.
    Emily Caporello
    Dr. Emily Caporello, Program Director, Division of Translational Research - NINDS, NIH
    Paige Cramer Lacatena
    Paige Cramer Lacatena, Director Business Development and Licensing, HQ Neurology - Merck
    Ana Moreno
    Ana Moreno, CEO and Founder - Navega Therapeutics
    Paul Mieyal
    Dr. Paul Mieyal, Managing Director - Outcome Capital, LLC
    Todd Bertoch
    Todd Bertoch, Chief Executive Officer at JBR Clinical Research - CenExel
  11. Spurring Biotech Innovation And Access Across the Globe: A High- Level Discussion
    Breakout Session
    • Emerging Opportunities in Global Markets
    30DE
    Marwan Abdulaziz Janahi
    Marwan Abdulaziz Janahi, Senior Vice President - Dubai Science Park
    Lise Alter
    Lise Alter, General Manager - French Health Innovation Agency
    Mansoor Al Mansoori
    Mansoor Al Mansoori, Chairman, Abu Dhabi Department of Health - UAE
  12. Start-Up Stadium Tuesday Morning
    Start-Up Stadium 5B
  13. Strengthening of the Clinical Trials Environment in Europe Under the Accelerating Clinical Trials (ACT EU) Initiative
    Breakout Session
    • Clinical Trials Innovations
    31C
    Laura Pioppo
    Ms. Laura Pioppo, ACT EU Programme manager - European Medicines Agency (EMA)
    Nathalie Seigneuret
    Nathalie Seigneuret, Senior Scientific Project Manager - Innovative Health Initiative (IHI)
    Claire Skentelbery
    Dr. Claire Skentelbery, Director General - EuropaBio
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
    Thomas Bols
    Thomas Bols, Head of Government Affairs and Patient Engagement, EMEA & APAC - PTC Therapeutics
  14. Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics
    Breakout Session
    • Brain Health
    26A
    Alaa Halawa
    Alaa Halawa, Executive Director and Head of Healthcare, US Ventures - Mubadala Capital
    Richard Shea
    Mr. Richard Shea, CEO - Basking Biosciences
    Carol Suh
    Carol Suh, Co-founder & Chief Operating Officer - Neumora
    Joanne Taylor
    Joanne Taylor, Senior Vice President, Research - Gain Therapeutics
    Craig Thompson
    Craig Thompson, CEO - Cerevance
  15. What is Needed for Gene Therapy in the Future and How Close Are We?
    Session
    Larry Foreman
    Larry Foreman, CEO - CHO-Plus
11:15 AM – 11:30 AM
(PST)
  1. ICEX SPAIN TRADE & INVESTMENT
    Global Innovation Hub 30 December 1899 05:00:00
    Maria J. Fernandez
    Ms. Maria J. Fernandez, Trade Commissioner - Trade Commission of Spain in Chicago - ICEX Spain Trade & Investment
11:30 AM – 1:00 PM
(PST)
  1. Polish Investment and Trade Agency
    Global Innovation Hub 30 December 1899 05:00:00
    Zuzanna Kobrzynski
    Zuzanna Kobrzynski, Polish Investment and Trade Agency - Polish Investment and Trade Agency
  2. Premier & General Attendee Lunch
    Session Sails Pavilion
11:45 AM – 12:00 PM
(PST)
  1. Swiss Biotech Association
    Global Innovation Hub 30 December 1899 05:00:00
    Michael Altorfer
    Dr. Michael Altorfer, CEO - Swiss Biotech Association
12:00 PM – 12:15 PM
(PST)
  1. Hong Kong Science & Technology Parks Corporation
    Global Innovation Hub 30 December 1899 05:00:00
    Grace Lau
    Grace Lau, Head, Institute for Translational Research - Hong Kong Science and Technology Parks Corporation
12:15 PM – 1:30 PM
(PST)
  1. UK Government Department for Business and Trade
    Global Innovation Hub 30 December 1899 05:00:00
    Raffaella Harvey
    Mrs. Raffaella Harvey, Senior Manager, Biopharmaceuticals - Department for Business and Trade
  2. Super Session
    Where to Launch? Expanding Beyond Home and Activating Your Product’s Global Potential
    Super Session
    • Emerging Opportunities in Global Markets
    28ABCDE
    Sponsored by:
    Cencora
    Sandra Anderson
    Sandra Anderson, Senior Vice President - Cencora
    Grant Castor
    Grant Castor, Senior Vice President, Commercial Strategy and Operations - Sentynl Therapeutics, Inc.
    Glenn Pauly
    Glenn Pauly, Chief Commercial Officer - Alzheon
    Joel Prieve
    Joel Prieve, Senior Vice President, Licensing and Mergers & Acquisitions - Outlook Therapeutics
    Peter Radovich
    Peter Radovich, President & Chief Operating Officer - Mirum Pharma
12:30 PM – 12:45 PM
(PST)
  1. Taiwan BIO
    Global Innovation Hub 30 December 1899 05:00:00
    Wallace Lin
    Dr. Wallace Lin, Secretary-General - Taiwan BIO
12:45 PM – 1:00 PM
(PST)
  1. Belgian Pavilion
    Global Innovation Hub 30 December 1899 05:00:00
    Willem Dhooge
    Mr. Willem Dhooge, COO - Flanders.Bio
1:30 PM – 2:45 PM
(PST)
  1. Student Program: An Introduction to the Biotechnology Industry
    Special Program
    • Diversity‚ Equity and Inclusion
    29AB
    Pete Pellerito
    Pete Pellerito, Senior Policy Adviser Federal/State Economic Development & Technology Transfer Lead - BIO
    Kollet Koulianos
    Kollet Koulianos, Senior Payer Advisor - Hemophilia Alliance
    Thomas Miller
    Dr. Thomas Miller, Global Head, Acute, Chronic & Pediatric Disease Nucleus - Bayer
    Stanley Maloy
    Stanley Maloy, Emeritus Associate VP for Innovation and Professor of Microbiology - San Diego State University
1:45 PM – 2:45 PM
(PST)
  1. Accelerating the Globalization of Cell and Gene Therapies
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Jennifer Rabin
    Jennifer Rabin, Specialist Leader - Deloitte Consulting LLP
    Shahrukh Hashmi
    Shahrukh Hashmi, Faculty - Mayo Clinic
    Sumant Ramachandra
    Sumant Ramachandra, CEO - Impact Bio
    Robert Hughes
    Robert Hughes, Global Head of Technical Operations - Galapagos
    Kristen Sudol
    Kristen Sudol, Vein to Vein Supply Chain - Johnson & Johnson
    Peter Holman
    Peter Holman, VP of Quality - Arsenal Bio
    Xiaoxi (Sofie) Wei
    Dr. Xiaoxi (Sofie) Wei, CEO & Co-Founder - X-Therma
  2. AI/ML is Transforming R&D and Business
    Breakout Session
    • AI and Digital Health
    24BC
    Maude Tessier
    Dr. Maude Tessier, Chief Business Officer - Seismic Therapeutic
    Karen Akinsanya
    Karen Akinsanya, President, R&D - Therapeutics - Schrodinger, Inc.
    Jiye Shi
    Jiye Shi, Vice President - Eli Lilly
    Joe McDonald
    Joe McDonald, Chief Data Officer - Odyssey Therapeutics
    Frank Grams
    Frank Grams, Chief Commercial Officer - Partex NV
  3. Creative Claiming for Platforms & Products: Designing an IP Strategy to Go Global
    Breakout Session
    • Intellectual Property
    26B
    Tanis Keirstead
    Dr. Tanis Keirstead, Partner - Mewburn Ellis
    Malathi Lakshmikumaran
    Dr. Malathi Lakshmikumaran, Executive Director and Practice Head - Lakshmikumaran & Sridharan
    Yoon Suk SHIN
    Ms. Yoon Suk SHIN, Senior Partner/Patent Attorney - Lee International IP & Law
    Amy Feng
    Ms. Amy Feng, Managing Partner - Wu, Feng & Zhang
    Patricia Campbell
    Dr. Patricia Campbell, IP Partner - Jones Day
  4. Fireside Chat
    Fireside Chat with Robert A. Bradway, Chairman and Chief Executive Officer, Amgen
    Fireside Chat
    • Business Development and Finance
    25ABC
    John Crowley
    John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)
    Robert Bradway
    Robert Bradway, Chief Executive Officer and Chairman - Amgen
  5. Growth Opportunities from Women’s Health Investments
    Breakout Session
    • Business Development and Finance
    30DE
    Sheila Mikhail
    Sheila Mikhail, Board Member, Women's Health Access Matters; Executive Director - BC Ruckus
    Mary Beth Cicero
    Mary Beth Cicero, Co-Founder and CEO - 3Daughters
    Julia Owens
    Dr. Julia Owens, CEO - Verto Therapeutics
    Megan Greenfield
    Megan Greenfield, Partner - McKinsey & Co
  6. How Should Biotechs Plan and Partner with CROs and Other Providers to Deliver Clinical Research and Maximize the Value of their Asset?
    Breakout Session
    • Business Development and Finance
    23BC
    Sponsored by:
    fortrea logo
    Tom Pike
    Tom Pike, Chairman and Chief Executive Officer - Fortrea
    Jennifer Byrne
    Jennifer Byrne, Founder and CEO - Javara
    Michael Norton
    Michael Norton, Senior Advisor - Boston Consulting Group
    Gadi Saarony
    Gadi Saarony, CEO - Advarra
  7. Joining Forces to Accelerate Innovation in Oncology
    Breakout Session
    • Oncology
    30ABC
    Sponsored by:
    Genentech logo
    Mandy Jackson
    Mandy Jackson, Managing Editor (US Commercial News) - Scrip
    Visali Ramanathan
    Visali Ramanathan, Executive Director, Head of Business Development for Oncology - Genentech
    Gregor Fachinger
    Gregor Fachinger, VP, Head of Oncology & Immuno-Oncology Business Development - Merck KGaA
    Susan Graf
    Susan Graf, Biotech Executive, Board Member & Advisor
    Mira Chaurushiya
    Mira Chaurushiya, Senior Partner - Westlake Village BioPartners
  8. NIH Support for Minority Health and Health Disparities Focused on Early-Stage Life Science Companies
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Dave Whelan
    Dave Whelan, Managing Director - Bespoke Strategies
    Michael Banyas
    Mr. Michael Banyas, Program Manager - National Institute of Minority and Health Disparities
    Corine Farewell
    Dr. Corine Farewell, Director UVM Innovations - University of Vermont
    Anna Lisa Somera
    Anna Lisa Somera, CEO - Rhaeos
    Ke Zhang
    Ke Zhang, Founder and interim CEO - Allerdia Inc.
  9. Promising Advances in Neuroscience: New Molecular Targets and Biomarkers
    Breakout Session
    • Brain Health
    26A
    Hank Safferstein
    Dr. Hank Safferstein, Senior Advisor - UPMC Enterprises
    Susanne Ahmari
    Susanne Ahmari, Assistant Professor, Department of Psychiatry - University of Pittsburgh
    Amit Etkin
    Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience
    Craig Thompson
    Craig Thompson, CEO - Cerevance
  10. Strategies for Antimicrobial Access in LMICs
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Jomana Musmar
    Dr. Jomana Musmar, Executive Director of the Presidential Advisory Council for Combating Antibiotic - Resistant Bacteria (PACCARB)
    Yann Ferrisse
    Mr. Yann Ferrisse, Business Development & Partner Engagement Director - GARDP Foundation
    Kevin Outterson
    Prof. Kevin Outterson, Executive Director - CARB-X
    Monika Schneider
    Dr. Monika Schneider, Director, Global AMR Policy - Shionogi
  11. The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
    Special Program
    • Business Development and Finance
    32AB
    Chad Wessel
    Chad Wessel, Director, Industry Analysis - Biotechnology Innovation Organization (BIO)
2:00 PM – 4:00 PM
(PST)
  1. Health~Holland
    Global Innovation Hub 30 December 1899 05:00:00
    Wieteke Wouters
    Wieteke Wouters, Program Director - HollandBIO
  2. Start-Up Stadium Tuesday Afternoon
    Start-Up Stadium 5B
2:15 PM – 2:30 PM
(PST)
  1. European Innovation Council
    Global Innovation Hub 30 December 1899 05:00:00
    Robert Schröder
    Robert Schröder, Head of Sector External Communication (EISMEA) - European Innovation Council
2:20 PM – 2:30 PM
(PST)
  1. Panel Discussion on Improving Expression and Manufacturing of Novel Biologics
    Session
2:30 PM – 2:45 PM
(PST)
  1. Department of Health Abu Dhabi
    Global Innovation Hub 30 December 1899 05:00:00
    Asma Al mannaei
    Dr. Asma Al mannaei, executive director of Research and innovation center - Department of Health - Abudhabi
2:45 PM – 3:00 PM
(PST)
  1. Dubai Science Park
    Global Innovation Hub 30 December 1899 05:00:00
3:00 PM – 4:00 PM
(PST)
  1. Breaking the Cycle: Innovations in Addressing Substance Use Disorder
    Breakout Session
    • Brain Health
    26A
    Tam Nguyen
    Dr. Tam Nguyen, Program Officer - National Institute on Drug Abuse (NIDA)
    James Hickman
    Dr. James Hickman, Professor of NanoScience, Chemistry, Biomolecular Science, Physics and Electrical Engineering, University of Central Florida; Chief Scientist - Hesperos
    Courtney Miller
    Dr. Courtney Miller, Founder, Myosin Therapeutics; Professor Department of Molecular Medicine, Department of Neuroscience - UF Scripps Biomedical Research
    Joanne Peterson
    Joanne Peterson, Founder and Executive Director - Learn to Cope
    Retsina Meyer
    Dr. Retsina Meyer, Head of Corporate Strategy - Delix
  2. Building a More Sustainable Biopharma Innovation Ecosystem
    Breakout Session
    • Environmental Sustainability
    29C
    Rachel Kaufman
    Rachel Kaufman, Head of Global Sustainability - Avantor
    Joydeep Ganguly
    Joydeep Ganguly, Senior Vice President of Corporate Operations, and Chief Sustainability Officer - Gilead Sciences
    Mark Steen
    Mark Steen, VP, Sustainability and Climate Initiatives - Corning
    Sharon Vidal
    Sharon Vidal, Global Head of Corporate Social Responsibility and Sustainability - Illumina
  3. Fireside Chat
    Fireside Chat with Joshua Boger, PhD, Founder and Former CEO of Vertex Pharmaceuticals; Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
    Fireside Chat
    • Business Development and Finance
    25ABC
    Amber Tong
    Amber Tong, Senior Editor - endpoints news
    Joshua Boger
    Dr. Joshua Boger, Founder and Former CEO of Vertex Pharmaceuticals - Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
  4. From Incubation to Acquisition: The Growth Journey of an Early-Stage Company
    Breakout Session
    • Business Development and Finance
    30ABC
    Sponsored by:
    johnson and johnson
    Melinda Richter
    Melinda Richter, Global Head - Johnson & Johnson
    Matt Lorenzi
    Matt Lorenzi, Vice President - Johnson & Johnson
    Colin Farlow
    Colin Farlow, Co-Founder and CEO - Serotiny
    Eric Moessinger
    Eric Moessinger, Partner - +ND Capital
    Leo MacDonald
    Leo MacDonald, Vice President - Johnson & Johnson Innovative Medicine
  5. Getting Personal: How the Evolving U.S. Privacy Legal Landscape Impacts Biomedical Research
    Breakout Session
    • AI and Digital Health
    24BC
    Justin Pine
    Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)
    Kimberly Gold
    Kimberly Gold, Chief Privacy Officer - Genentech
    Paul Friedrichs
    Paul Friedrichs, Maj. Gen. (ret), Deputy Assistant to the President - Director of the Office of Pandemic Preparedness and Response at the White House
    Carla Cartwright
    Carla Cartwright, Head Global Digital and Regulatory Policy - Johnson & Johnson
    David Schwartz
    David Schwartz, Partner - Arnold & Porter
  6. Microgravity: A Strategic Advantage in R&D
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Elizabeth Reynolds
    Ms. Elizabeth Reynolds, Managing Director - Starburst Aerospace
    Rob Garmise
    Rob Garmise, Director of Formulations Development, Exploratory Biopharmaceutics - Bristol Myers Squibb
    Paul Reichert
    Mr. Paul Reichert, Associate Principal Scientist - Merck
    Kate Rubins
    Kate Rubins, Astronaut - NASA
  7. Optimizing the Investability of Your Lead Program: Data-Driven Approaches for Pipeline Prioritization
    Breakout Session
    • Business Development and Finance
    32AB
    Drew Cutshaw
    Dr. Drew Cutshaw, Senior Associate, Medical Officer - Pappas Capital
    Ben Davis
    Ben Davis, Vice President, Corporate Alliances - IQVIA
    Mike Grey
    Mike Grey, Chairman - Plexium
    Susan Lenderts
    Ms. Susan Lenderts, Head of Life Sciences - SAS Institute, INC
    Lauren Crawford Shaver
    Lauren Crawford Shaver, Head of Healthcare and Life Sciences for the Americas, Senior Managing Director - FTI Consulting
  8. Preparing for Platforms: Sponsor and Regulator Perspectives on the Platform Technology Designation (PTD)
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Dylan Bechtle
    Mr. Dylan Bechtle, US Regulatory Policy Lead - Johnson & Johnson
    Rob Berlin
    Rob Berlin, Head US Regulatory Policy - GSK
    Snehal Naik
    Snehal Naik, Head of Regulatory Policy - Spark Therapeutics
    Anne-Virginie Eggimann
    Anne-Virginie Eggimann, Chief Regulatory Officer - Tessera Therapuetics
    Antonella Lozito
    Antonella Lozito, Executive Director, Regulatory Strategy, Infectious Diseases - Moderna
    Nicole Verdun
    Dr. Nicole Verdun, Super Office Director, CBER - FDA
  9. Super Session
    Superconvergence: How the AI, Genetics, and Biotechnology Revolutions Will Transform our Lives, Work, and World, new book from Jamie Metzl
    Super Session
    • Next Generation Biotherapeutics
    28ABCDE
    Jamie Metzl
    Jamie Metzl, Founder and Chair - OneShared.World
  10. The Bad and the Ugly: Unpacking Repercussions of the Medicaid Drug Rebate Program Rule
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    29AB
    Patrick Plues
    Patrick Plues, SVP, State Government Relations - Biotechnology Innovation Organization
    Alice Valder Curran
    Ms. Alice Valder Curran, Partner - Hogan Lovells
    Matt Salo
    Matt Salo, CEO - Salo Health Strategies
    Melanie Lendnal
    Melanie Lendnal, Senior Vice President of Policy & Advocacy - ALS Association
  11. Workforce, Diversity, Equity, and Inclusion at BIO: Presenting New Survey Data and Exploring Partnerships
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Ted Love
    Dr. Ted Love, Chair - BIO Board of Directors
    Jane Barry-Moran
    Jane Barry-Moran, Managing Director, Programs & Research - Out Leadership
    Charlotte Jones-Burton
    Charlotte Jones-Burton, Founder - Women of Color in Pharma
    Mark Royal
    Mark Royal, Senior Client Partner - Korn Ferry
    Mike Edmondson
    Mike Edmondson, U.S. Vice President, Performance Optimization - Amgen
3:15 PM – 3:30 PM
(PST)
  1. Japan Bioindustry Association
    Global Innovation Hub 30 December 1899 05:00:00
    Yoshiaki Tsukamoto
    Mr. Yoshiaki Tsukamoto, Executive Director - Japan Bioindustry Association
3:30 PM – 3:40 PM
(PST)
  1. Bioprocess Insider Interviews: Syngene
    Session
4:00 PM – 5:00 PM
(PST)
  1. Jamie Metzl Book Signing
    Special Program Sails Pavilion
4:15 PM – 5:15 PM
(PST)
  1. Adaptive Reuse: Biomanufacturing Enters A New Age
    Breakout Session
    • Environmental Sustainability
    29C
    Matt Gardner
    Matt Gardner, Board Chairman - California Biomanufacturing Center
    TJ Silvey
    TJ Silvey, Director - Raymond James
    Gordon Zagar
    Gordon Zagar, President & Founder - ZCI
    Ella Woger-Nieves
    Ella Woger-Nieves, CEO - Invest Puerto Rico
    Ann-Stewart Patterson
    Ann-Stewart Patterson, Executive Vice President - CBRE
  2. AI-Generated Invention and the Future of Bio R&D
    Breakout Session
    • Intellectual Property
    26B
    Hans Sauer
    Hans Sauer, Deputy General Counsel, VP for IP - Biotechnology Innovation Organization (BIO)
    Ryan Abbott
    Prof. Ryan Abbott, Partner - Brown, Neri, Smith & Khan, LLP
    Andrei Iancu
    Mr. Andrei Iancu, Partner - Sullivan & Cromwell LLP
    Sarah Korman
    Ms. Sarah Korman, General Counsel - Isomorphic Labs
  3. Becoming an Early Innovation Partner of Choice
    Breakout Session
    • Business Development and Finance
    29AB
    David Kane
    David Kane, Managing Partner - Arc Bio Communications
    Helena Chaye
    Helena Chaye, CEO - KaliVir
    Peter Sandor
    Peter Sandor, Head of Corporate Strategy - Astellas Pharma Inc
    Olga Granaturova
    Olga Granaturova, Co-Founder/President - PriveBio
    Anna Chen
    Anna Chen, Principal - Frazier Life Sciences
  4. Best Practices for Managing Your Biotech’s Ca$hflow
    Breakout Session
    • Business Development and Finance
    32AB
    Joel Papernik
    Mr. Joel Papernik, Member - Mintz
    Barbara Wood
    Ms. Barbara Wood
    Robert Easton
    Mr. Robert Easton - Eastern Strategy, LLC
    Heidi Henson
    Ms. Heidi Henson, Director - Lisata Therapeutics
  5. Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
    Breakout Session
    • Brain Health
    26A
    Heather McKenzie
    Ms. Heather McKenzie, Senior Editor - BioSpace
    Laxminarayan Bhat
    Dr. Laxminarayan Bhat, CEO - Reviva Pharmaceuticals Inc
    Amit Etkin
    Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience
    Daniel Karlin
    Daniel Karlin, Chief Medical Officer - Mind Medicine (MindMed)
    David Benshoof Klein
    David Benshoof Klein, Co-Founder and CEO - Click Therapeutics
  6. Exploring the Future of Gene Delivery: A Conversation on the Direction for Next-Generation Vectors
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Ola Tuvesson
    Mr. Ola Tuvesson, Chief Technology Officer - NorthX Biologics
    Johan Rockberg
    Prof. Johan Rockberg, Professor at the Royal Institute of Technology and Director of GeneNova - Royal Institute of Technology
    Amy Walker
    Amy Walker - 4BaseBio PLC
    Henk Streefkerk
    Henk Streefkerk, CEO & Medical Director - Amarna Therapeutics
    Jayesh Kulkarni
    Jayesh Kulkarni, co-founder and CSO
  7. Exploring the Uncharted: Rare Diseases, Unintended Consequences of the Inflation Reduction Act, and Demonstrating the Value of These Therapies
    Breakout Session
    • Orphan and Rare Disease
    30DE
    Sponsored by:
    alexion logo
    Michele Oshman
    Michele Oshman, SVP of Patient Advocacy - Biotechnology Innovation Organization (BIO)
    Karin Hoelzer
    Dr. Karin Hoelzer, Senior Director, Policy and Regulatory Affairs - National Organization for Rare Disorders (NORD)
    Kate Jones
    Kate Jones, Head of Federal Affairs - Alexion, AstraZeneca Rare Disease
    Jason Spangler
    Jason Spangler, Chief Executive Officer - Innovation and Value Initiative’s (IVI)
    Dionne Stalling
    Dionne Stalling, Executive Director - Rare And Black
  8. Fireside Chat
    Fireside Chat with Dr. Vivian Ota Wang, PhD, Deputy Director, NIH Office of Research on Women's Health
    Fireside Chat
    • Diversity‚ Equity and Inclusion
    25ABC
    Sheila Mikhail
    Sheila Mikhail, Board Member, Women's Health Access Matters; Executive Director - BC Ruckus
    Vivian Ota Wang
    Vivian Ota Wang, Deputy Director - NIH Office of Research on Women's Health
  9. Super Session
    Fireside Chat with John McDonald, Corporate Vice President, Global Head of Business Development and M&A, Novo Nordisk
    Super Session
    • Business Development and Finance
    28ABCDE
    Sponsored by:
    novo nordisk
    Mandy Jackson
    Mandy Jackson, Managing Editor (US Commercial News) - Scrip
    John McDonald
    John McDonald, Corporate Vice President - Novo Nordisk
  10. Future of Biopharma Innovation: Unleashing the Potential of Emerging Therapeutic Modalities in Oncology and Beyond
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Romain Bonnot
    Romain Bonnot, Principal - ZS Associates
    Falk Ehmann
    Dr. Falk Ehmann, Head of Innovation and Development Accelerator (IDeA) - European Medicines Agency (EMA)
    Lucas Donigian
    Lucas Donigian, Executive Director, Business Development - Zymeworks Inc.
    Jesper Haaning
    Jesper Haaning, Head of Development External Innovation - Novo Nordisk
    Malik Kaman
    Malik Kaman, Principal - ZS Associates
  11. Highlighting the Power of Patient Organizations: Exploring Initiatives That Drive Equitable Impact for Patients and Communities
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Deepa Dahal
    Ms. Deepa Dahal, Co-founder and Partner - DKI Health
    Mary Stutts
    Ms. Mary Stutts, Chief Executive Officer - Healthcare Businesswomen's Association
    Joseph Nadglowski
    Mr. Joseph Nadglowski, President and Chief Executive Officer - Obesity Action Coalition
    Christine Verini
    Ms. Christine Verini, CEO - CancerCare
    Sonali Chopra
    Ms. Sonali Chopra, Executive Director, Patient Advocacy Relations - Genentech a Member of the Roche Group
  12. The Future of Immunology: Path to Precision Medicine
    Breakout Session
    • Diagnostics and Personalized Medicine
    24BC
    Sponsored by:

    merck logo

    Max Bayer
    Max Bayer, Reporter - endpoints news
    Aileen Lorenzo Pangan
    Aileen Lorenzo Pangan, Vice President & Therapeutic Area Head - Merck
    Cynthia Bens
    Cynthia Bens, Senior Vice President - Personalized Medicine Coalition
    Andres Hurtado-Lorenzo
    Andres Hurtado-Lorenzo, Senior Vice President - Crohn's and Colitis Foundation
    Stephan Targan
    Stephan Targan, Executive Director, F. Widjaja Inflammatory Bowel Disease Institute - Cedars-Sinai
9:00 AM – 10:30 AM
(PST)
  1. Keynote: Admiral William H. McRaven, U.S. Navy Four-Star Admiral (Retired)
    Main Stage Program Ballroom 20
    John Crowley
    John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)
    William McRaven
    William McRaven, U.S. Navy Four-Star Admiral (Retired)
  2. Main Stage Opening Program
    Main Stage Program Ballroom 20
    John Crowley
    John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)
    Jason Kelly
    Dr. Jason Kelly, Chair, National Security Commission on Emerging Biotechnology - Co-Founder and CEO, Gingko Bioworks
10:30 AM – 4:10 PM
(PST)
  1. Incorporating New Technologies in Development and Production, Regulatory Landscapes, and Agile Manufacturing
    BioProcess Theater BioProcess Theater
11:00 AM – 1:00 PM
(PST)
  1. Achieving Commercial Success Through the National Institutes of Health's Intramural Research Program
    Breakout Session
    • Business Development and Finance
    32AB
    Michael Salgaller
    Dr. Michael Salgaller, Supervisory Specialist, National Cancer Institute Tech Transfer Center - National Institutes of Health (NIH)
    Maggie Scully
    Dr. Maggie Scully, Director, Partnership Development Office - Frederick National Laboratory for Cancer Research
    Jeffery Alexander
    Dr. Jeffery Alexander, Director, Innovation Policy - RTI International
    Mark Rohrbaugh
    Dr. Mark Rohrbaugh, Special Advisor for NIH Technology Transfer - National Institutes of Health (NIH)
    Richard Colvin
    Richard Colvin, Chief Medical Officer - bluebird bio
  2. Biotech Partnering in Stormy Seas: Key Insights on Charting a Course to Successful Deal-Making through a Choppy Market
    Breakout Session
    • Business Development and Finance
    29AB
    Kate Hillier
    Kate Hillier, Partner - Cooley LLP
    Joseph Baroldi
    Mr. Joseph Baroldi, Executive Vice President, Chief Business Officer Ionis Pharmaceuticals - Ionis Pharmaceuticals
    Barbara Kosacz
    Mrs. Barbara Kosacz, COO and General Counsel - Kronos Bio
    Stacy Feld
    Stacy Feld, Regional Head - Johnson & Johnson
  3. Breaking the Rare Disease Deadlock through Multi-Stakeholder Collaboration
    Breakout Session
    • Orphan and Rare Disease
    26A
    Niklas Blomberg
    Dr. Niklas Blomberg, Executive Director - Innovative Health Initiative
    Annette Bakker
    Dr. Annette Bakker, President - Children's Tumor Foundation
    Klaus Romero
    Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Deborah Requesens
    Dr. Deborah Requesens, Director, JumpStart Program - Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
    Claire Skentelbery
    Dr. Claire Skentelbery, Director General - EuropaBio
  4. How to De-Risk Drug Development from the Earliest Stages
    Breakout Session
    • Business Development and Finance
    23BC
    Sponsored by:
    parexel biotech
    Seema Kumar
    Seema Kumar, CEO - Cure at 345 Park Avenue
    Wyatt Gotbetter
    Wyatt Gotbetter, Senior Vice President and Worldwide Head, Access Consulting - PAREXEL
    Abhiram Rao
    Abhiram Rao, Director - EQT Life Sciences
    Ned Wydysh
    Ned Wydysh, Vice President - Health Advances, LLC
    Dan Gold
    Dan Gold, Retired President and CEO - MEI Pharma
    Susan Billings
    Susan Billings, Chief Commercial Officer - Vivodyne
  5. Open Innovation in Life Sciences, Decades of Experiences, Time to Regroup!
    Breakout Session
    • Translational Research
    31AB
    Lucie Rochard
    Dr. Lucie Rochard, External Engagement Lead, R&D - Sanofi
    Karen Chandross
    Karen Chandross, Head, Strategic Initiatives and Scientific Relations N.A. • R&D North America - Sanofi
    Pamela Hill
    Pamela Hill, Sr. Director, Head of Open Innovation Program - Astra Zeneca
    Florian Montel
    Florian Montel, Head of Open Sciences - Boehringher Ingelheim
    Vinit Nijhawan
    Vinit Nijhawan, Managing Director - Mass Ventures
  6. Perspectives from Women Powerbrokers
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Joshua Fox
    Mr. Joshua Fox, Member - Mintz
    Laura Indolfi
    Laura Indolfi, Chief Executive Officer and Co-Founder - PanTher Therapeutics
    Anna Turetsky
    Ms. Anna Turetsky, Principal, Venture Investments - The Mark Foundation for Cancer Research
    Sheila Gujrathi
    Sheila Gujrathi, Chairwoman and Director - ADARx, Ventyx, ImmPACT, Janux
    Sabrina Johnson
    Ms. Sabrina Johnson, President and CEO - Daré Bioscience, Inc.
  7. Post-Guidance Opportunities and Challenges with Prescription Drug Use-Related Software (PDURS)
    Breakout Session
    • AI and Digital Health
    24BC
    Rob Berlin
    Rob Berlin, Head US Regulatory Policy - GSK
    Eva Temkin
    Eva Temkin, Partner - Arnold & Porter
    Renee Beaver
    Renee Beaver, Director, Corporate Counsel - Otsuka America Pharmaceutical, Inc
  8. Rising to the Challenge of Science Regulation: Ensuring Public Policy Keeps Pace with Innovation Ecosystem
    Breakout Session
    • Widening the Bioeconomy
    29C
    Tad Sonstegard
    Tad Sonstegard, Chief Executive & Scientific Officer - Acceligen
    Cameron Bishop
    Cameron Bishop, Head of Washington Office - J.R. Simplot Company
    Emily Carlton
    Emily Carlton, SAF Policy Specialist - LanzaJet
  9. Start-Up Stadium Wednesday Morning
    Start-Up Stadium 5B
  10. Using AI/ML for Identification and Optimization of Therapeutic Molecules
    Breakout Session
    • AI and Digital Health
    30ABC
    Sponsored by:
    johnson and johnson
    Michal Preminger
    Michal Preminger, Regional Head - Johnson & Johnson Innovation East North America
    Justin Scheer
    Justin Scheer, Vice President, Global Head, In Silico Discovery - Johnson & Johnson Innovative Medicine
    Mark DePristo
    Mark DePristo, CEO and Co-Founder - BigHat Biosciences
    Joe McDonald
    Joe McDonald, Chief Data Officer - Odyssey Therapeutics
    Eeshit Dhaval Vaishnav
    Eeshit Dhaval Vaishnav, Founder and CEO - Sequome
    Jim Edwards
    Jim Edwards, Venture Partner - Samsara BioCapital Partner
11:30 AM – 1:00 PM
(PST)
  1. Premier & General Attendee Lunch
    Session Sails Pavilion
12:00 PM – 5:00 PM
(PST)
  1. Company Presentations Wednesday
    Company Presentation Session Company Presentation Theaters
    Sponsored by:
    johnson and johnson
12:15 PM – 1:30 PM
(PST)
  1. Super Session
    From Chasing My Cure to Every Cure: Dr. David Fajgenbaum on the Power of AI to Repurpose Medicines [LUNCH IN ROOM]
    Super Session
    • Patient Advocacy
    28ABCDE
    Michele Oshman
    Michele Oshman, SVP of Patient Advocacy - Biotechnology Innovation Organization (BIO)
    David Fajgenbaum
    David Fajgenbaum, Associate Professor of Medicine (Translational Medicine and Human Genetics), Perelman School of Medicine, University of Pennsylvania; - Co-Founder & President, Every Cure
1:30 PM – 2:45 PM
(PST)
  1. Student Program: Entry into Early Careers in Biotechnology
    Special Program
    • Diversity‚ Equity and Inclusion
    29AB
    Stanley Maloy
    Stanley Maloy, Emeritus Associate VP for Innovation and Professor of Microbiology - San Diego State University
    Ann Lee-Karlon
    Ann Lee-Karlon, Chief Executive Officer and President - EpiBiologics
    Sonali Chopra
    Ms. Sonali Chopra, Executive Director, Patient Advocacy Relations - Genentech a Member of the Roche Group
    Justin Scheer
    Justin Scheer, Vice President, Global Head, In Silico Discovery - Johnson & Johnson Innovative Medicine
    Steven Bloom
    Steven Bloom, Chief Business Officer - Vincerx Pharma
1:45 PM – 2:45 PM
(PST)
  1. Advancing Innovation: Best Practices for University-Industry Collaboration
    Breakout Session
    • Translational Research
    31AB
    Ed Pagani
    Dr. Ed Pagani, Executive Director, Office for External Partnerships, and Assistant VP, External Partnerships - Duke University
    Doug Krafte
    Doug Krafte, Site Head – Durham, North Carolina, and Sr. Vice President, Ion Channels/Transporters - OmniAb
    Caroline Lowenthal
    Ms. Caroline Lowenthal, Alliance Manager - MIT
    Sunita Rajdev
    Sunita Rajdev, Director - Licensing and Strategic Alliances, Life Sciences - Stanford University
    Tari Suprapto
    Dr. Tari Suprapto, Director, Search & Evaluation (Western US & Canada) - Novo Nordisk
  2. Applied AI & Advanced Automation in Clinical Development
    Breakout Session
    • AI and Digital Health
    30ABC
    Sponsored by:
    propharma
    Bryan Katz
    Bryan Katz, Chief Strategy Officer - ProPharma
    Kirk Wroblewski
    Kirk Wroblewski, Chief Information Officer - ProPharma
  3. Biotech Innovations for Pet Health
    Breakout Session
    • Widening the Bioeconomy
    29C
    Ellen Carlin
    Ellen Carlin, Vice President - Pathway Policy Group
    Tammie Wahaus
    Tammie Wahaus, CEO - Elias Animal Health LLC
    Dylan Balsz
    Dylan Balsz, CEO - Anivive Lifesciences
    Hervé Poulet
    Hervé Poulet, Director of Strategic Partnering for Animal Health - Boehringer Ingelheim
  4. Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
    Breakout Session
    • Business Development and Finance
    32AB
    Elise Simard
    Mrs. Elise Simard, Speaker Trainer/Coach - LaVoieHealthScience
    Donna LaVoie
    Mrs. Donna LaVoie, Founder & CEO - LaVoieHealthScience
  5. Cell Therapy Primer
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    23BC
    Kevin Curran
    Dr. Kevin Curran, Scientific Advisor and Instructor - BioTech Primer
  6. Diversifying the Talent Pipeline: Industry-Recognized Curriculum for a Skilled Workforce
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Vicki Brannock
    Ms. Vicki Brannock, Senior Director Workforce Strategy & Innovation - Biocom California Institute
    Scott Eaker
    Mr. Scott Eaker, Chief Operations Officer - Prolacta
    Judith Velasco
    Mrs. Judith Velasco, Executive Director - Verdugo Workforce Development Board
    Willie Zuniga
    Mr. Willie Zuniga, Retired, Former President and Site Head - Grifols Biologicals
    Linnea Fletcher
    Dr. Linnea Fletcher, Executive Director - InnovATEBIO, National Biotechnology Center
  7. New Tools, New Times: Chemical and Structural AI for Drug Discovery
    Breakout Session
    • AI and Digital Health
    24BC
    Ayman AlAbdallah
    Mr. Ayman AlAbdallah, Partner - Mubadala Capital
    Lee Cronin
    Prof Lee Cronin, Founder and Chief Executive Officer - Chemify
    Raphael Townshend
    Mr. Raphael Townshend, Founder & CEO - Atomic AI
    Tom Miller
    Tom Miller, CEO and co-founder - Iambic Therapeutics
  8. Pioneering Paths: Navigating the Frontiers of First-in-Class
    Breakout Session
    • Next Generation Biotherapeutics
    30DE
    Sponsored by:
    bayer
    Juergen Eckhardt
    Juergen Eckhardt, EVP and Head of Leaps by Bayer - Head of Business Development & Licensing, Pharmaceuticals Division, Bayer
    Hanadie Yousef
    Hanadie Yousef, Chief Executive Officer and Co-Founder - Juvena Therapeutics
    Seth Ettenberg
    Seth Ettenberg, President and CEO - BlueRock Therapeutics
    John Wu
    John Wu, Managing Director and Partner - Boston Consulting Group
    Aleksandra Rizo
    Aleksandra Rizo, CEO - Vividion
  9. The Oncology Endgame: Assemble and Shine with AI and Precision Medicine, or Lose.
    Breakout Session
    • Oncology
    26B
    Karim Budhwani
    Dr. Karim Budhwani, CEO-Scientist - CerFlux
    Sandeep Menon
    Dr. Sandeep Menon, Chief Development Officer, Head of Development and Safety - Alnylam
    Maggie Scully
    Dr. Maggie Scully, Director, Partnership Development Office - Frederick National Laboratory for Cancer Research
    Kara Bortone
    Kara Bortone, Senior Director, J&J Innovative Medicine Business Development - Johnson & Johnson
2:00 PM – 4:00 PM
(PST)
  1. Start-Up Stadium Wednesday Afternoon
    Start-Up Stadium 5B
3:00 PM – 4:00 PM
(PST)
  1. AI's Impact on Oncology Cancer Drug Development
    Breakout Session
    • Oncology
    26B
    Wyatt McDonnell
    Dr. Wyatt McDonnell, CEO & Co-founder - Infinimmune
    Kamni Vijay
    Kamni Vijay, CEO - Enable Medicine
    Jakob Dupont
    Jakob Dupont, Executive Partner - Sofinnova Investments
    Abe Heifets
    Abe Heifets, CEO & Co-Founder - Atomwise
    Andrei Georgescu
    Ms. Andrei Georgescu, CEO - Vivodyne
    Daniel Silva Manzano
    Mr. Daniel Silva Manzano, CEO & Co-Founder - Monod Bio
  2. Blueprints for Biotech: Designing Deals that Deliver
    Breakout Session
    • Business Development and Finance
    32AB
    Matthew Hudes
    Mr. Matthew Hudes, Founder & CEO - bdlBiologx
    Bryan Glaser
    Dr. Bryan Glaser, Senior Vice President, Business Development - Invenra Inc.
    Grace Han McMahon
    Ms. Grace Han McMahon, Associate Vice President and Head of Merck’s BD&L Pacific Innovation Hub - Merck
    Saira Ramasastry
    Ms. Saira Ramasastry, Partner - Sanacor
    Christopher Walsh
    Dr. Christopher Walsh, Senior Vice President, General Counsel - Denali Therapeutics Inc.
  3. Developing Successful DEI Programs for Life Sciences Companies
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Marredia Crawford
    Ms. Marredia Crawford, Chief Inclusion, Diversity and Equity Officer - Baker McKenzie
    Nicole Stovall
    Nicole Stovall, AVP, Diversity Strategy and Innovation - Merck
    Alessandra Ravetti
    Alessandra Ravetti, Senior Vice President, Associate General Counsel - Regeneron Pharmaceuticals
    Matthew Silversten
    Matthew Silversten, Head of Litigation, Investigations, Employment & Governance - Astellas
  4. Driving Biotech Success: What Every CEO Needs from Her C-Level Team
    Breakout Session
    • Business Development and Finance
    29AB
    Mary Haak-Frendscho
    Dr. Mary Haak-Frendscho, President and CEO - Spotlight Therapeutics
    Karen Boezi
    Ms. Karen Boezi, Chief Operating Officer - Thirona Biosciences
    Cindy Dunkle
    Ms. Cindy Dunkle, Chief People Officer - Denali
    Seema Kantak
    Dr. Seema Kantak, Senior Vice President, Biotherapeutics - Exelixis
  5. Navigating the Intersection of National Security and Advances in Emerging Biotechnology
    Breakout Session
    • Widening the Bioeconomy
    29C
    Phyllis Arthur
    Phyllis Arthur, Senior Vice President, Infectious Disease & Emerging Science Policy - Biotechnology Innovation Organization (BIO)
    Alina Meltaus
    Alina Meltaus, Chief of Staff - National Security Commission on Emerging Biotechnology
    Steven Moss
    Steven Moss, Senior Policy Advisor - National Security Commission on Emerging Biotechnology
    Keeley Mui
    Keeley Mui, Senior Policy Advisor - National Security Commission on Emerging Biotechnology
  6. Obesity Therapies: Present and Future Opportunities
    Breakout Session
    • Business Development and Finance
    30ABC
    Sponsored by:
    novo nordisk
    Tomas Landh
    Tomas Landh
    Brian Bloomquist
    Brian Bloomquist, Chief Business and Strategy Officer - Alveus Therapeutics
    Kasper Veje
    Kasper Veje, Vice President, Head of Diabetes & Obesity Search and Evaluation - Novo Nordisk
    Andrew Whittle
    Andrew Whittle, Director, Strategic Partnering, Cardiometabolism & Retinal Health - Boehringer Ingelheim
    Su Zhang
    Su Zhang, VP, Global Head of Business Development - Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  7. Organizing to Derisk Academic Assets
    Breakout Session
    • Translational Research
    31AB
    Michelle Hoffmann
    Dr. Michelle Hoffmann, Executive Director - Chicago Biomedical Consortium
    Aleks Baranczak
    Dr. Aleks Baranczak, Chief Program Officer - Blackbird Labs
    Lisa Dhar
    Dr. Lisa Dhar, Associate Vice President for Innovation and New Ventures - Northwestern Innovation and New Ventures Office
    Jonathan Young
    Dr. Jonathan Young, Head of WARF Therapeutics - Wisconsin Alumni Research Foundation (WARF)
    Raheleh Hatami
    Raheleh Hatami, Scientific Collaboration Director - Deerfield Management
  8. PDABs and the IRA: The Impact of Federal Legislation on State-Level Prescription Pricing Practices
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    23BC
    Elizabeth (Liz) Helms
    Elizabeth (Liz) Helms, President and CEO - California Chronic Care Coalition
    Brett Johnson
    Brett Johnson, Director, State Government Affairs - Amgen
    John O’Brien
    Dr. John O’Brien, President and CEO - National Pharmaceutical Council
    Alice Valder Curran
    Ms. Alice Valder Curran, Partner - Hogan Lovells
    Tiffany Westrich-Robertson
    Tiffany Westrich-Robertson, Chief Executive Officer and Co-Founder - AiArthritis
  9. PFDDs and Beyond: Different Roads to Patient-Inspired Drug Development
    Breakout Session
    • Patient Advocacy
    25ABC
    Sponsored by:
    travere
    Sika Dunyoh
    Sika Dunyoh, Senior Director of Patient Advocacy - Travere Therapeutics
    Danaé Bartke
    Danaé Bartke, Person living with HCU, Executive Director - HCU Network America
    Reenie McCarthy
    Reenie McCarthy, CEO - Stealth BioTherapeutics
    Stacey Frisk
    Stacey Frisk, Executive Director - Rare Disease Company Coalition
    Jessica Tome Garcia
    Jessica Tome Garcia, Associate Director, Research Programs - The Michael J. Fox Foundation for Parkinson's Research
  10. The Promise of Personalized Treatment Becoming Reality: How INT Could Change Oncology
    Breakout Session
    • Oncology
    26A
    Sponsored by:

    merck logo

    Cynthia Bens
    Cynthia Bens, Senior Vice President - Personalized Medicine Coalition
    Niklas Blomberg
    Dr. Niklas Blomberg, Executive Director - Innovative Health Initiative
    Scot Ebbinghaus
    Scot Ebbinghaus, Vice President and Therapeutic Area Head - Merck Research Laboratories
    Michelle Brown
    Michelle Brown, Vice President, Portfolio Lead - Moderna
    Alicia Walker Rowell
    Alicia Walker Rowell, Vice President - AIM at Melanoma
  11. Thriving in the Age of Digital Insecurity: New Reporting Obligations and Cyber Resilience for Life Sciences Companies
    Breakout Session
    • AI and Digital Health
    24BC
    Justine Phillips
    Ms. Justine Phillips, Partner - Baker McKenzie
    Nick Arico
    Nick Arico, Supervisory Special Agent - US Department of Justice, Federal Bureau of Investigation
    Todd Hemmen
    Todd Hemmen, Chief, Cyber Technical Analytics and Operations Section, Cyber Division - US Department of Justice, Federal Bureau of Investigation
    Lisel Newton
    Lisel Newton, Senior Director, Information Security, Risk & Compliance - Gossamer Bio
    Anne Blake-Dreher
    Anne Blake-Dreher, Vice President and Assistant General Counsel - Perrigo
  12. Vaccinating Against Mistrust and Misinformation During an Infodemic
    Breakout Session
    • Infectious Disease and Vaccines
    30DE
    Amy Speak
    Ms. Amy Speak, Senior Director, Corporate Communications - Novavax, Inc.
    Reed Tuckson
    Dr. Reed Tuckson, Managing Director / Co-Founder - Tuckson Health Connections, LLC / Black Coaliition Against COVID-19
    Pedro Martinez
    Mr. Pedro Martinez, Director, Health - UnidosUS
    Miriam Mason
    Miriam Mason, Senior Advisor - Public Good Projects (PGP)
4:15 PM – 5:15 PM
(PST)
  1. Adult Vaccination: New Vaccines, New Opportunities to Protect Public Health
    Breakout Session
    • Infectious Disease and Vaccines
    32AB
    Sponsored by:

    merck logo

    Phyllis Arthur
    Phyllis Arthur, Senior Vice President, Infectious Disease & Emerging Science Policy - Biotechnology Innovation Organization (BIO)
    Jannie Oosthuizen
    Jannie Oosthuizen, President, Merck Human Health U.S. - Merck
    Abby Bownas
    Abby Bownas, Manager - Adult Vaccine Access Coalition
    Michael Hodin
    Michael Hodin, CEO; Managing Partner - Global Coalition on Aging; High Lantern Group
    Jia Hu
    Jia Hu, CEO - 19 to Zero
  2. Biotech as Climate Tech: Sustainable Production in Pharma, Ag, and Industry
    Breakout Session
    • Widening the Bioeconomy
    29C
    Angela Ailloni
    Angela Ailloni, VP, Business Development - Ginkgo Bioworks
    Adrienne Davenport
    Adrienne Davenport, Managing Director - BASF Bioservices
    Christina Smolke
    Christina Smolke, CEO - Antheia, Inc
    Sasha Calder
    Sasha Calder, Head of Impact - Geno
  3. Co-opting Biological Processes to Drug Cancer and Other Diseases
    Breakout Session
    • Oncology
    26B
    Mariana Mihalusova
    Mariana Mihalusova, Investor - Venrock
    Larry Hamann
    Dr. Larry Hamann, Co-founder/CEO - Interdict Bio
    Bernd Boidol
    Mr. Bernd Boidol, CEO - Proxygen
    Aetna Wun Trombley
    Aetna Wun Trombley, CEO - Lycia
    George Eliades
    George Eliades, CEO - Mythic Therapeutics, Inc.
  4. Enhancing Clinical Trial Diversity Through a Patient-Centric, Data Driven Approach
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Elena Martinez
    Elena Martinez, Professor, Herbert Wertheim School of Public Health and Human Longevity Science; Associate Director of Population Sciences - UC San Diego Moores Cancer Center
    Trevan Locke
    Dr. Trevan Locke, Assistant Research Director - Duke-Margolis Institute for Health Policy
    Megan Fesinmeyer
    Megan Fesinmeyer, Observational Research Senior Manager - Amgen
    Carla Rodriguez-Watson
    Carla Rodriguez-Watson, Director of Research - Reagan-Udall Foundation for the FDA
    Darryl Sleep
    Darryl Sleep, Head, Global Public Health - Amgen
  5. Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    23BC
    Stephen Morales
    Mr. Stephen Morales, Senior Principal - Blue Fin Group, An IntegriChain Company
    Gerry Gleeson
    Gerry Gleeson, Head of US Market Access - Sanofi
    Bill Sarraille
    Bill Sarraille, Adjunct Professor - University of Maryland Francis King Carey School of Law
    Bill Roth
    Bill Roth, Founding Partner - Blue Fin Group
    Albert Thigpen
    Albert Thigpen, Operating Advisor - Nautic Partners
  6. Fireside Chat
    Fireside Chat with FDA Commissioner Dr. Robert Califf
    Fireside Chat
    • Regulatory Innovation
    25ABC
    John Crowley
    John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)
    Robert Califf
    Robert Califf, FDA Commissioner - U.S. Food and Drug Administration
  7. IPOs Are Starting to Come Back: Are You Ready?
    Breakout Session
    • Business Development and Finance
    29AB
    Rich Ramko
    Mr. Rich Ramko, Partner, US Biotech Leader - EY (Ernst & Young)
    Brad Wolff
    Brad Wolff, Senior Managing Director |Global Advisory | Strategic Advisory | Mergers and Acquisition - Evercore
    Steven Spector
    Steven Spector, Executive Vice President, Head of Business Development and General Counsel - Longboard Pharma
    Arvind Kush
    Arvind Kush, CFO - RayzeBio
    Kristin VanderPas
    Kristin VanderPas, Partner - Cooley
  8. Moving from the Lab Bench to the Biotech C-Suite: Insights on Running a Founder-Led Biotech
    Breakout Session
    • Translational Research
    31AB
    Max Bayer
    Max Bayer, Reporter - endpoints news
    Trevor Martin
    Mr. Trevor Martin, CEO and Co-founder - Mammoth Biosciences
    Jordi Mata-Fink
    Mr. Jordi Mata-Fink, CEO and Co-founder - Gate Bioscience
    Kevin Parker
    Kevin Parker, CEO and Co-founder - Cartography Biosciences
    Kira Poskanzer
    Dr. Kira Poskanzer, Founder-in-Residence - Arcadia Science
    Heather Bowerman
    Ms. Heather Bowerman, CEO & Founder - DotLab
  9. Overcoming Systemic Data Bias via AI and Digital Health Tools: Perspectives from Providers, Pharma and Innovators
    Breakout Session
    • AI and Digital Health
    24BC
    Alexis Bortniker
    Alexis Bortniker, Partner - Cooley LLP
    Shane Case
    Shane Case, Global Head of Privacy, Ethics and Policy Governance - Illumina
    Erin Parks
    Erin Parks, Co-founder and Chief Clinical Officer - Equip Health
  10. Policy and Practice Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Precision Oncology
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Daryl Pritchard
    Dr. Daryl Pritchard, Senior Vice President - Personalized Medicine Coalition
    Peter Hulick
    Dr. Peter Hulick, Medical Director, Center for Personalized Medicine - NorthShore / Endeavor Health
    Jonathan Katchmore
    Jonathan Katchmore, Vice President of Commercial Diagnostic Strategy - Eli Lilly
    Robert Dumanois
    Mr. Robert Dumanois, Director, Reimbursement Strategy - Thermo Fisher Scientific
    Wendy Levin
    Wendy Levin, Chief Medical Officer - Biofidelity
9:00 AM – 10:00 AM
(PST)
  1. Achieving the WHO Cervical Cancer Elimination Targets: The Value of Innovation in Achieving Pivotal Public Health Goals
    Breakout Session
    • Infectious Disease and Vaccines
    23BC
    Sponsored by:

    merck logo

    Citseko Staples Miller
    Citseko Staples Miller, Managing Director, Healthcare and Life Science - FTI Consulting
    Jenelle Krishnamoorthy
    Jenelle Krishnamoorthy, Vice President, Head of Global Public Policy and International Affairs - Merck
    Beth Battaglino
    Beth Battaglino, CEO - HealthyWomen
    Joanna Sickler
    Joanna Sickler, Vice President - Roche Diagnostics
  2. Exploring Deal-Making Options for Your Portfolio of Assets
    Breakout Session
    • Business Development and Finance
    29AB
    Nisha Nanda
    Dr. Nisha Nanda, Group Vice President, Business Development - Eli Lilly
    Bassil Dahiyat
    Dr. Bassil Dahiyat, President and Chief Executive Officer - Xencor, Inc.
    James Mutamba
    Dr. James Mutamba, Chief Business Officer - Arrakis Therapeutics
    Adam Rosenthal
    Dr. Adam Rosenthal, CEO and Founder - Star Therapeutics
    Caroline Stark Beer
    Caroline Stark Beer, Chief Business Officer - Jnana Therapeutics
  3. Immune System Biomarkers: Can Our Antibodies Predict How We Will React to Disease and Immunotherapy?
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Moira Gunn
    Dr. Moira Gunn, Radio Host - BiotechNation
    G. Scott Chandler
    Dr. G. Scott Chandler, Global Head, Personalized Health Care (PHC) Safety - F. Hoffmann-La Roche
    Justina Fert-Bober
    Dr. Justina Fert-Bober, Project Scientist - Cedars Sinai Medical Center
    Martin Gouldstone
    Martin Gouldstone, Chief Executive Officer - Oncimmune
    Prem Premsrirut
    Prem Premsrirut, CEO and President - Mirimus
  4. New Approaches in Radiopharmaceuticals
    Breakout Session
    • Oncology
    31AB
    Karen Tkach Tuzman
    Karen Tkach Tuzman, Director of Biopharma Intelligence, Head of Discovery and Preclinical Research - BioCentury
    Dave Greenwald
    Dr. Dave Greenwald, CEO of Aviko Radiopharmaceuticals and vice president, business development - Deerfield Management
    Ken Song
    Ken Song, former CEO - RayzeBio
    Suji Jeong
    Dr. Suji Jeong, Founding Partner - The SJR Group
    Jeevan Virk
    Jeevan Virk, Therapeutic Area Strategy Head - Novartis
  5. Revolutionizing Clinical Trials: Patient Registries, Wearable Tech, and Video Capture
    Breakout Session
    • Clinical Trials Innovations
    26B
    Klaus Romero
    Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Jason Colquitt
    Jason Colquitt, CEO - Across Healthcare
    Tina Duong
    Dr. Tina Duong, Director of Clinical Outcomes Research and Development - Stanford University
    Allison Moore
    Mrs. Allison Moore, Founder/CEO - Hereditary Neuropathy Foundation
    Michelle Campbell
    Dr. Michelle Campbell, Associate Director, Stakeholder Engagement & Clinical Outcomes, Office of Neuroscience - FDA
  6. Surviving Turbulence: Extending Runway and Creating Value in Healthcare and Biotech
    Breakout Session
    • Business Development and Finance
    32AB
    Gwendolyn Wu
    Gwendolyn Wu, Reporter - BioPharma Dive
    Ayman AlAbdallah
    Mr. Ayman AlAbdallah, Partner - Mubadala Capital
    Nate Chang
    Nate Chang, Operating Partner, Life Sciences - Playground Global
    Andy Seid
    Andy Seid, Partner - Bioluminescence Ventures
    Carolyn Ng
    Dr. Carolyn Ng, Partner and Managing Director - TPG Life Sciences Innovations
  7. The US Supreme Court and the End of Scientific Deference?
    Breakout Session
    • Regulatory Innovation
    31C
    Stacy Amin
    Stacy Amin, Former FDA Chief Counsel - Morrison Foerster
    Zach Howe
    Zach Howe, Assistant U.S. Attorney, Southern District of California
    Vanessa Burrows
    Vanessa Burrows, Partner - Simpson Thacher & Bartlett LLP
    Judy Haron
    Judy Haron, Assistant General Counsel - PhRMA
  8. What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology
    Breakout Session
    • Oncology
    24BC
    Angus Liu
    Angus Liu, Deputy Editor - Fierce Pharma
    Keir Loiacono
    Keir Loiacono, Chief Executive Officer - BlueSphere Bio
    Dan Passeri
    Dan Passeri, Chief Executive Officer - Cue Biopharma
    David Fontana
    David Fontana, Chief Operating and Chief Business Officer - Umoja Biopharma
    Lola Fashoyin-Aje
    Lola Fashoyin-Aje, Director, Office of Clinical Evaluation|(Cellular, Tissue, Gene Therapies) - Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
10:15 AM – 11:15 AM
(PST)
  1. Advancing the Global Regulatory Decision-Making with Public Private Partnerships
    Breakout Session
    • Regulatory Innovation
    31C
    Susan Winckler
    Ms. Susan Winckler, CEO - Reagan-Udall Foundation for the FDA
    Klaus Romero
    Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Peter Marks
    Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) - U.S. Food and Drug Administration
    Adora Ndu
    Adora Ndu, Chief Regulatory Affairs Officer - BridgeBio
    Carlos Garner
    Carlos Garner, Senior Vice President, Global Regulatory Affairs - Eli Lilly
  2. Approaching the Tipping Point: The Emergence of Allogeneic Cell Therapy for Oncology
    Breakout Session
    • Oncology
    31AB
    George Eastwood
    Mr. George Eastwood, Board Chair/Interim Executive Director - The Emily Whitehead Foundation
    Abigail Jenkins
    Abigail Jenkins, Former President & CEO - Gamida Cell
    P.K. Morrow
    Dr. P.K. Morrow, Senior Vice President and Head of Oncology Therapeutic Area Unit - Takeda
    Cokey Nguyen
    Dr. Cokey Nguyen, Chief Scientific and Technical Officer - Atara Biotherapeutics
    Kristin Yarema
    Dr. Kristin Yarema, President & CEO - Poseida Therapeutics
  3. Changing the Game: Innovation to End HIV
    Breakout Session
    • Infectious Disease and Vaccines
    23BC
    Cecilia Chung
    Cecilia Chung, Senior Director, Strategic Initiatives and Evaluation - Transgender Law Center
    Micheal Ighodaro
    Micheal Ighodaro, Co-Executive Director - Prevention Access Campaign
    Jenelle Krishnamoorthy
    Jenelle Krishnamoorthy, Vice President, Head of Global Public Policy and International Affairs - Merck
    Ji Ma
    Ji Ma, Head of Discovery - Brii Biosciences
    Sandra Thurman
    Sandra Thurman, Senior Advisor to the Division of Global HIV and Tuberculosis - CDC
  4. Competing as a Diagnostic Company in the Current Funding Environment: New Funding Models
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Jonathan Grinstein
    Jonathan Grinstein, Senior Editor - Inside Precision Medicine
    Bernard Peperstraete
    Dr. Bernard Peperstraete, CEO and Co-Founder - AcuamarkDx
    Michele Colucci
    Michele Colucci, Founder & Managing Partner - DigitalDx Ventures
    Alan Liu
    Alan Liu, Founder and Chief Operating Officer - Persperion Diagnostics
  5. Inside the VC Playbook: Overcoming Obstacles in Challenging Markets for Success
    Breakout Session
    • Business Development and Finance
    32AB
    Andrei Georgescu
    Ms. Andrei Georgescu, CEO - Vivodyne
    Jakob Dupont
    Jakob Dupont, Executive Partner - Sofinnova Investments
    Andrew Lam
    Andrew Lam, Head of Biotech Investment - Ally Bridge Group
    Enoch Kariuki
    Enoch Kariuki, President - Endeavor Biomedicines
    Carol Gallagher
    Carol Gallagher, Independent Director
  6. Is Oncology Still a Hot Spot for Biopharma Deals?
    Breakout Session
    • Oncology
    24BC
    Ashwin Singhania
    Ashwin Singhania, Partner/Principal - EY (Ernst & Young)
    Camille Landis
    Camille Landis, Chief Business Officer and Chief Financial Officer - T-knife Therapeutics
    Ben Hickey
    Ben Hickey, President - RayzeBio
    Christopher Mortko
    Dr. Christopher Mortko, Vice President, Head of Search and Evaluation, Business Development & Licensing - Merck
    Ross Aarons
    Ross Aarons, Director, Corporate Development - Jazz Pharmaceuticals
  7. Partnering with ARPA-H: New Opportunities and Best Practices for Engaging a Transformative R&D Funder
    Breakout Session
    • Business Development and Finance
    29AB
    Susan Monarez
    Dr. Susan Monarez, Deputy Director - Advanced Research Projects Agency for Health (ARPA-H)
    Jason Roos
    Dr. Jason Roos, Director, Scalable Solutions - Advanced Research Projects Agency for Health (ARPA-H)
    Wade Shen
    Wade Shen, Director, Proactive Health - Advanced Research Projects Agency for Health (ARPA-H)
    Yoseph Kim
    Yoseph Kim, CEO - Optosurgical
    Stan Wang
    Stan Wang, CEO & Founder - Thymmune
  8. Regulators & DTRA Enabling DCTs
    Breakout Session
    • Clinical Trials Innovations
    26B
    Amir Kalali
    Dr. Amir Kalali, Co Chair - DTRA
    Rasika Kalamegham
    Rasika Kalamegham, Head US Regulatory Policy - Genentech
    Jane Myles
    Jane Myles, Program Director - DTRA
    Steffen Thirstrup
    Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Michelle Campbell
    Dr. Michelle Campbell, Associate Director, Stakeholder Engagement & Clinical Outcomes, Office of Neuroscience - FDA
10:30 AM – 1:00 PM
(PST)
  1. Company Presentations Thursday
    Company Presentation Session Company Presentation Theaters
    Sponsored by:
    johnson and johnson
  2. Risked Based Approach Commissioning and Qualification for organizations
    BioProcess Theater BioProcess Theater
11:00 AM – 1:00 PM
(PST)
  1. Start-Up Stadium Thursday
    Start-Up Stadium 5B
  2. Talent Development for a Digital World